COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC), ACCORDING TO THE RECOMMENDED BRAZILIAN GUIDELINES FOR HTA

被引：0
|
作者：
Saggia, M. G. [1 ]
Nasciben, V. D. [2 ]
Santos, E. V. [1 ]
机构：
[1] Roche Pharmaceut, Hlth Econ, Sao Paulo, Brazil
[2] Prod Roche Quim & Farmaceut, Hlth Econ, Sao Paulo, Brazil
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [31] Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis
    Wu, Zehua
    Deng, Yanhong
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (12)
  • [32] Sequential Bevacizumab-based therapy in metastatic colorectal cancer (mCRC): results of a treatment sequencing cost analysis
    Rautenberg, T.
    Siebert, U.
    Arnold, D.
    Bennouna, J.
    Kubicka, S.
    Walzer, S.
    Ngoh, C.
    ONKOLOGIE, 2012, 35 : 56 - 56
  • [33] COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE plus OXALIPLATIN) VERSUS FOLFOX-4 (5-FU/LV + OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Prolla, G.
    Borges, L. G.
    Santos, E.
    VALUE IN HEALTH, 2010, 13 (07) : A268 - A269
  • [34] Capecitabine Plus Irinotecan Versus 5-FU/Leucovorin Plus Irinotecan in the Treatment of Colorectal Cancer: A Meta-analysis
    Guo, Yuanbiao
    Shi, Min
    Shen, Xiaoheng
    Yang, Chen
    Yang, Liu
    Zhang, Jun
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 110 - 118
  • [35] Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group
    Punt, Cornelis J. A.
    Simkens, Lieke H.
    Van Rooijen, Johan
    Van de Wouw, Agnes W.
    Loosveld, Olaf
    Creemers, Geert-Jan
    Hendriks, Mathijs P.
    Los, Maartje
    Van Alphen, Robbert Jeroen
    Polee, Marco
    Muller, Erik W.
    Van der Velden, Ankie
    Van Voorthuizen, Thymen
    Koopman, Miriam
    Mol, Linda
    Kwakman, Johannes J.
    van Werkhoven, Erik D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] A META-ANALYSIS AND COST-MINIMIZATION ANALYSIS OF OXALIPLATIN-BASED CHEMOTHERAPY VERSUS IRINOTECAN-BASED CHEMOTHERAPY WITH TARGETED MOLECULAR AGENTS IN THE FIRST-LINE TREATMENT OF METASTATIC ADVANCED COLORECTAL CANCER IN CHINA
    Zhang, X.
    Su, W.
    Lin, Z.
    Bao, T.
    Jian, Y.
    Xuan, J.
    VALUE IN HEALTH, 2022, 25 (01) : S120 - S120
  • [37] Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong
    Zhou, Keary R.
    Cheng, Ashley
    Ng, W. T.
    Kwok, T. Y.
    Yip, Elton Y. P.
    Yao, Rosa
    Leung, P. Y.
    Lee, V. W. Y.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (05) : 541 - 548
  • [38] Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study
    Li, Wenhua
    Chang, Jinjia
    Wang, Chenchen
    Peng, Junjie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] EXPLORATORY ANALYSIS OF APAC VALUES VERSUS RECOMMENDED TREATMENT GUIDELINES FOR METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Piedade, A.
    Goes, L.
    Henriques, R. S.
    Borges, L.
    VALUE IN HEALTH, 2015, 18 (07) : A826 - A827
  • [40] Sequential capecitabine-based treatment of patients with metastatic colorectal cancer (MCRC) combined with oxaliplatin first-line: A retrospective analysis.
    Hoeffkes, HG
    Arland, M
    Freidank, A
    Ranze, O
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 277S - 277S
12345